Hemato Oncology Testing Market
Hemato Oncology Testing Market Analysis By Component (Services, Assay Kits & Reagents), By Technology (PCR,IHC, NGS, Cytogenetics), By Cancer Type (Leukemia, Lymphoma, Hodgkin Lymphoma ,Others), By End User & By Region - Global Market Insights 2023 to 2033
Analysis of Hemato Oncology Testing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Hemato Oncology Testing Market Outlook (2023 to 2033)
Rising at a CAGR of 18.5%, the global hemato oncology testing market is projected to increase from a valuation of US$ 4.33 billion in 2023 to US$ 23.64 billion by the end of 2033.
Hematology oncology tests are further classified into services, assay kits & reagents. Global demand for assay kits & reagents is expected to increase at an impressive CAGR of 20% from 2023 to 2033.
Assay kits are used in various applications, including examining disease pathways, screening for prospective drug candidates, and analyzing biopharmaceutical production processes, drug discovery & development, life science research, and environmental monitoring.
A reagent, also known as an analytical reagent, is a substance or compound that is added to a system in chemistry to bring about a chemical reaction or check to see whether a reaction happens. Although the terms 'reagent' and 'reactant' are frequently used synonymously, reactant refers to a material that is consumed during a chemical reaction.
Furthermore, rising demand for drug discoveries, the requirement for biotechnology research, and the widespread prevalence of infectious diseases are all driving sales of assay kits & reagents. The assay kits' capacity to reduce ambiguity by providing accurate diagnostic results is also boosting sales growth.
Demand for hemato oncology testing services is predicted to expand at a CAGR of 17.5% during the forecast period. This can be ascribed to the rising incidence of leukemia, non-Hodgkin lymphoma, and myeloma malignancies as well as the growing knowledge of cutting-edge medicines such as customized drugs.
In contrast to traditional medicine, precision medicine is a novel approach to healthcare that is known as individualized medicine and is based on each patient's unique genetic composition.
- For instance, in May 2022, Thermo Fisher Scientific and the Qatar Genome Program (QGP), a branch of the Qatar Foundation (QF), partnered to progress genomic research and clinical applications of predictive genomics in Qatar as a move toward widening the benefits of precision medicine to Arab populations worldwide.
- Furthermore, the Erasmus Medical Center's academic hematology division was one of the first medical facilities in the world to provide each multiple myeloma patient with novel diagnostic testing services in July 2019. By assessing over 92 genes in the various cancer cells, this service aids the medical practitioner in predicting myeloma's aggressiveness.
As a result, it is anticipated that the availability of advanced services for the diagnosis of myeloma is likely to drive market growth during the projection period.
| Report Attributes | Details |
|---|---|
| Hemato Oncology Testing Market Size (2023E) | US$ 4.33 Billion |
| Forecasted Market Value (2033F) | US$ 23.64 Billion |
| Global Market Growth Rate (2023 to 2033) | 18.5% CAGR |
| China Market Growth Rate (2023 to 2033) | 24% CAGR |
| Japan Market Growth Rate (2023 to 2033) | 13.5% CAGR |
| Canada Market Growth Rate (2023 to 2033) | 16.5% CAGR |
| Germany Market Growth Rate (2023 to 2033) | 15% CAGR |
| Key Companies Profiled | Abbott Laboratories; Adaptive Biotechnologies; Archerdx, Inc.; Arup Laboratories, Inc.; Asuragen, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd.; Illumina, Inc.; Invivoscribe, Inc.; Molecularmd (Subsidiary of Icon PLC); Qiagen N.V.; Sanofi SA; Thermo Fisher Scientific, Inc. |
Why is Demand for Hemato Oncology Testing Products Progressing Rapidly?
“Rising Prevalence of Blood-related Diseases & Cancers”
The science involved in the treatment, diagnosis, and prevention of conditions related to the blood, including cancer, is known as hemato oncology. The increasing prevalence of lymphoma and myeloma is boosting the growth of the hemato oncology testing market.
- For instance, according to the GLOBOCAN database of the International Agency for Research on Cancer, the incidence of non-Hodgkin lymphoma was 544 thousand worldwide in 2020, and this number is projected to rise to 834 thousand by 2040.
- The same source also stated that by 2040, there will be 510 thousand new cases of myeloma cancer worldwide, up from 325 thousand cases in 2020.
As a result, the rising prevalence of non-lymphoma Hodgkin's and myeloma cancers around the world is increasing the demand for at-home hematology testing products.
- Globally, 475 thousand instances of leukaemia were reported in 2020, according to the International Agency for Research on Cancer's GLOBOCAN 2020 database. By 2040, this number is projected to rise to 692 thousand.
Thus, the increasing cases of hematopoietic cancer are boosting sales of hemato-oncology testing products and services.
“Growing Demand for Personalized Therapeutic Procedures”
Personalized medicine, which has gained popularity recently, strives to give each patient a treatment plan that is specifically designed for them based on the molecular cause of their illness. This personalized medicine demand is increasing due to the rising prevalence of different types of cancer, the affordability of personalized medicine therapy in the treatment of cancer and other diseases, the reduced side effects of personalized medicine therapeutic interventions, the high adoption rate in developed economies, and the advancement of novel drugs.
- For instance, the Medical Device Innovation Consortium began a pilot project in August 2022 as part of its somatic reference samples (SRS) program to enhance the regulatory assessment and validation process for cancer diagnoses based on next-generation sequencing (NGS). Reference samples are crucial to the validation process since these diagnostic tests must be confirmed for accuracy before being used in clinical settings.
“Development of Advanced Products for Diagnosis and Rapidly Increasing Rate of Senior Population”
The massive development of cutting-edge and novel molecular techniques for the diagnosis of hematomas and the growing acceptance of newly developed advanced techniques for the prognosis, diagnosis, and treatment of blood cancer are likely to positively boost the market growth.
- For instance, Burning Rock Biotech's NGS-based diagnostic tool, the “OverC Multi-Cancer Detection Blood Test”, got CE certification in June 2022.
The market for hemato oncology testing is also being driven by the growing rate of the elderly population, which leads to an increase in the incidence of hematologic cancer because this group of people is more susceptible to various chronic diseases. For the avoidance of adverse responses in patients and to lower mortality rates, doctors generally prefer medications paired with companion diagnostics because these patients need ongoing monitoring.
- According to the World Health Organization, there were roughly 1 billion persons aged 60 and older in 2021, and that number is expected to rise to 1.4 billion by 2030. Furthermore, the number of individuals in the world who are 60 or older is projected to double (to 2.1 billion) by 2050, while the number of people who are 80 or older is projected to triple during the same time.
“Adoption of AI in Cancer Diagnostic Techniques”
It is anticipated that the use of artificial intelligence (AI) in cancer diagnosis will accelerate market growth. Scientists have developed artificial intelligence tools to aid in screening procedures for several cancer types. AI-based computer algorithms have helped clinicians interpret mammograms for more than 20 years, but research in this field is developing quickly.
- For instance, the AI genomics start-up Freenome in the United States is concentrating on developing blood tests that use AI to find the body's early cancer warning signs. The company unveiled early results from research and development in October 2018 for using machine learning to detect colorectal cancer in its early stages.
to detect colorectal cancer in its early stages. What Hurdles & Challenges are Faced by Providers of Hemato Oncology Testing Products & Services?
“Unfavourable Reimbursement Policies”
The hemato-oncology testing demand is expanding quickly, but different regions' reimbursement difficulties may ultimately limit its growth. Hematology oncology test reimbursement policies differ significantly between nations.
Currently, the majority of nations' regulatory practices are not well suited to the market for hemato oncology testing. The current regulatory frameworks in such nations were designed for basic diagnostic procedures and are therefore inadequate for the development of innovative biomarker-based diagnostics.
“Challenges in Protecting Intellectual Property Rights”
The intellectual property rights of their cutting-edge diagnostic tests are posing difficulties for some market competitors. Even though pharmaceuticals can be patented, many nations still disagree about whether or not biomarkers should also be protected (biomarker detection is fundamental in companion diagnostics).
When a drug developer and a diagnostic developer work together to create intellectual property, the drug developer is typically interested in controlling ownership or exclusive licensing of any intellectual property associated with the product; in contrast, the diagnostic developer is typically interested in controlling intellectual property linked to the diagnostic and the general platform technology. The items created through such cooperation are currently not covered by any strong intellectual property legislation.
Issues may come up when licensing the new product to third parties if these entities share ownership of it. The earnings of the diagnostic developer who is a co-owner, for instance, will be impacted if the drug developer wants to license the diagnostic product to a rival diagnostic company. An exclusivity agreement can be struck to prevent these issues, but doing so may also provide other challenges.
For instance, the diagnostic developer may not be able to meet the market demand for the product after the drug developer and diagnostic developer jointly developed it. In these circumstances, the medication researcher will be forced to locate a different partner, which the exclusivity agreement will not permit.
Region-wise Analysis
Why is North America Dominating the Market for Hematology Oncology Testing Products?
“Rising Prevalence of Hematologic Cancer and Presence of Key Market Players”
North America is at the forefront of the development of the global market for hemato oncology testing. The high demand for diagnostic assays and services is being fueled by factors such as the rapid prevalence of hematologic cancer, the increasing rate of the ageing population, awareness of cutting-edge treatment options, and the strong presence of leading companies in the region.
The demand for blood cancer diagnostics in the U.S. is increasing significantly due to quick technological advancements and rising rates of cancer patients. The Americas hematology diagnostics market is expanding due to the rising prevalence of Hodgkin’s lymphoma, teens between 15-19 years of age are the main target patients in the nation. Academic and research organizations in the nation are strongly focused on the development of medical testing procedures.
- Additionally, the American Cancer Society reported in 2022 that there were approximately 60,650 new instances of leukaemia and 20,050 new cases of acute myeloid leukaemia (AML) in the country. Only 1% of malignancies were acute myeloid leukaemia (AML), which is rare cancer.
- For instance, the Canada Cancer Society announced in 2022 that 6,700 Canadians had been diagnosed with leukaemia in 2021, with 4,000 males and 2,700 women receiving the diagnosis.
Thus, the rising rate of blood cancer patients is boosting the demand for hematology oncology testing products and services in the region.
What is Supporting the Sales of Hemato Oncology Testing Technologies in Asia Pacific?
“Presence of Large Target Patient Pool”
By 2030, cancer cases are expected to increase to around 11 million in Asia, which already bears half of the world's burden of cancer. The increase is most likely the result of a population that is quickly getting older and is more prone to experience chronic disorders. Lung, blood, stomach, and liver cancers are among the most typical kinds of disease experienced in the region by the population.
Asia Pacific market is anticipated to enjoy the fastest growth in the coming years because of the region's large patient pool, affordable access to experienced technicians, and clear regulatory environment that promotes quicker product approvals. Additionally, there will likely be a rise in demand for cancer treatment and diagnostic procedures due to the rapidly expanding medical tourism industry in nations such as China, India, Japan, South Korea, and Malaysia.
What is the Demand Outlook for Hemato Oncology Testing Procedures in Europe?
“Rapid Developments in Diagnosis of Hemato Oncology”
The United Kingdom, Germany, France, and Italy are some of the leading European countries in the hemato oncology testing market. Europe is considered to be the fastest-growing sector in cancer genetic testing.
- In the last five years, there were over 2 million cases of common types of cancer in Germany, with over 600,000 new cases and 252 thousand fatalities, according to Globocan 2020 report.
The nation's increasing cancer rate has been mostly attributable to binge drinking and heavy smoking. The advancement of cancer research across the nation is greatly aided by strong institutional frameworks such as the German Cancer Consortium and major University Medical Center-based Comprehensive Cancer Centers (CCCs).
Also, the presence of strong research organizations, advanced healthcare facilities, and rapid advancements in the production of hemato oncology diagnostic equipment is generating potential opportunities in the hemato oncology testing market in the European region.
Category-wise Analysis
Which Technology is Highly Popular in This Industry?
“Low Cost & High Accuracy Aspects Driving Sales of PCR Testing Technologies”
Hemato oncology testing technologies are segmented into polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and cytogenetics. PCR testing technology is currently dominating sales growth, due to its simplicity of use, low cost, accuracy and efficiency offered, and convenience of availability.
- For instance, Abbott's RealTime IDH1 test recently made its debut, according to the Blood Center of Wisconsin's Diagnostic Laboratories. The bone marrow and blood samples of patients can be used in this PCR test to identify genetic variants in the IDH1 gene.
Therefore, the rising rate of PCR-based test launches is boosting market growth.
Demand for NGS-based testing in oncology is expected to increase rapidly during the forecast period, as this technology has many benefits, including improved sensitivity and specificity.
- For instance, the ClonoSEQ assay, an NGS-based test used to identify low amounts of cancer cells still present in patients diagnosed with multiple myeloma or lymphoblastic leukemia, was allowed to be marketed in September 2018 by the U.S. FDA.
As a result, it is also projected that an increasing number of FDA approvals for assays based on NGS is likely to boost market growth.
Competitive Landscape
Key players in the hemato oncology testing market are focused on developing advanced testing technologies. The sector is competitive and to maintain their market position leading companies are adopting strategies such as collaborations, mergers, new product launches, and more.
- For instance, the Mount Sinai Million Health Discoveries Program, a new human genome sequencing research initiative with the Regeneron Genetics Center (RGC), was launched in August 2022 by Mount Sinai Health System and the Icahn School of Medicine. The RGC's extensive gene sequencing capabilities and scientific research know-how is planned to be combined with Mount Sinai's huge and diversified patient population by the collaborative team.
- The iHope Genetic Health programme, which was launched in November 2021 by SAN DIEGO and Genetic Alliance, aims to give tens of thousands of people affected by genetic disorder access to whole-genome sequencing (WGS).
- To provide accessibility to precision oncology biomarker testing, Thermo Fisher Scientific introduced CE-IVD (IVDD) next-generation sequencing test and analytic software in August 2022.
Key Segments of Hemato Oncology Testing Industry Research
-
By Component :
- Services
- Assay Kits & Reagents
-
By Technology :
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Next-generation Sequencing (NGS)
- Cytogenetics
-
By Cancer Type :
- Leukemia
- Lymphoma
- Hodgkin Lymphoma
- Myeloproliferative Neoplasms
-
By End User :
- Hospitals
- Academic & Research Institutes
- Clinical Laboratories
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Pricing Analysis
- 5. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033)
- 6. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Component
- 6.1. Services
- 6.2. Assay Kits & Reagents
- 7. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Technology
- 7.1. Polymerase Chain Reaction (PCR)
- 7.2. Immunohistochemistry (IHC)
- 7.3. Next-generation Sequencing (NGS)
- 7.4. Cytogenetics
- 8. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Cancer Type
- 8.1. Leukemia
- 8.2. Lymphoma
- 8.3. Hodgkin Lymphoma
- 8.4. Myeloproliferative Neoplasms
- 9. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by End User
- 9.1. Hospitals
- 9.2. Academic & Research Institutes
- 9.3. Clinical Laboratories
- 10. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Region
- 10.1. North America
- 10.2. Europe
- 10.3. East Asia
- 10.4. South Asia
- 10.5. Latin America
- 10.6. Middle East & Africa (MEA)
- 10.7. Oceania
- 11. North America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. East Asia Market Analysis and Forecast
- 14. South Asia Market Analysis and Forecast
- 15. Latin America Market Analysis and Forecast
- 16. Middle East & Africa Market Analysis and Forecast
- 17. Oceania Market Analysis and Forecast
- 18. Global Market Analysis Key Countries
- 19. Competition Analysis
- 19.1. Abbott Laboratories
- 19.2. Adaptive Biotechnologies
- 19.3. Archerdx, Inc.
- 19.4. Arup Laboratories, Inc.
- 19.5. Asuragen, Inc.
- 19.6. Bio-Rad Laboratories, Inc.
- 19.7. F. Hoffman-La Roche Ltd.
- 19.8. Illumina, Inc.
- 19.9. Invivoscribe, Inc.
- 19.10. Molecularmd (Subsidiary of Icon PLC)
- 19.11. Qiagen N.V.
- 19.12. Sanofi SA
- 19.13. Thermo Fisher Scientific, Inc.
- 20. Appendix
- 21. Definitions of Analytical Frameworks
- 22. Sources and References
List Of Table
Table 01: Global Market Volume (Units), by Component, 2018 to 2033
Table 02: Global Market Value (US$ Mn), by Component, 2018 to 2033
Table 03: Global Market Volume (Units), by Technology, 2018 to 2033
Table 04: Global Market Value (US$ Mn), by Technology, 2018 to 2033
Table 05: Global Market Volume (Units), by Cancer Type, 2018 to 2033
Table 06: Global Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 07: Global Market Volume (Units), by End User, 2018 to 2033
Table 08: Global Market Value (US$ Mn), by End User, 2018 to 2033
Table 09: Global Market Volume (Units), by Region, 2018 to 2033
Table 10: Global Market Value (US$ Mn), by Region, 2018 to 2033
Table 11: North America Market Volume (Units), by Component, 2018 to 2033
Table 12: North America Market Value (US$ Mn), by Component, 2018 to 2033
Table 13: North America Market Volume (Units), by Technology, 2018 to 2033
Table 14: North America Market Value (US$ Mn), by Technology, 2018 to 2033
Table 15: North America Market Volume (Units), by Cancer Type, 2018 to 2033
Table 16: North America Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 17: North America Market Volume (Units), by End User, 2018 to 2033
Table 18: North America Market Value (US$ Mn), by End User, 2018 to 2033
Table 19: North America Market Volume (Units), by Country, 2018 to 2033
Table 20: North America Market Value (US$ Mn), by Country, 2018 to 2033
Table 21: Europe Market Volume (Units), by Component, 2018 to 2033
Table 22: Europe Market Value (US$ Mn), by Component, 2018 to 2033
Table 23: Europe Market Volume (Units), by Technology, 2018 to 2033
Table 24: Europe Market Value (US$ Mn), by Technology, 2018 to 2033
Table 25: Europe Market Volume (Units), by Cancer Type, 2018 to 2033
Table 26: Europe Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 27: Europe Market Volume (Units), by End User, 2018 to 2033
Table 28: Europe Market Value (US$ Mn), by End User, 2018 to 2033
Table 29: Europe Market Volume (Units), by Country, 2018 to 2033
Table 30: Europe Market Value (US$ Mn), by Country, 2018 to 2033
Table 31: East Asia Market Volume (Units), by Component, 2018 to 2033
Table 32: East Asia Market Value (US$ Mn), by Component, 2018 to 2033
Table 33: East Asia Market Volume (Units), by Technology, 2018 to 2033
Table 34: East Asia Market Value (US$ Mn), by Technology, 2018 to 2033
Table 35: East Asia Market Volume (Units), by Cancer Type, 2018 to 2033
Table 36: East Asia Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 37: East Asia Market Volume (Units), by End User, 2018 to 2033
Table 38: East Asia Market Value (US$ Mn), by End User, 2018 to 2033
Table 39: East Asia Market Volume (Units), by Country, 2018 to 2033
Table 40: East Asia Market Value (US$ Mn), by Country, 2018 to 2033
Table 41: South Asia Market Volume (Units), by Component, 2018 to 2033
Table 42: South Asia Market Value (US$ Mn), by Component, 2018 to 2033
Table 43: South Asia Market Volume (Units), by Technology, 2018 to 2033
Table 44: South Asia Market Value (US$ Mn), by Technology, 2018 to 2033
Table 45: South Asia Market Volume (Units), by Cancer Type, 2018 to 2033
Table 46: South Asia Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 47: South Asia Market Volume (Units), by End User, 2018 to 2033
Table 48: South Asia Market Value (US$ Mn), by End User, 2018 to 2033
Table 49: South Asia Market Volume (Units), by Country, 2018 to 2033
Table 50: South Asia Market Value (US$ Mn), by Country, 2018 to 2033
Table 51: Latin America Market Volume (Units), by Component, 2018 to 2033
Table 52: Latin America Market Value (US$ Mn), by Component, 2018 to 2033
Table 53: Latin America Market Volume (Units), by Technology, 2018 to 2033
Table 54: Latin America Market Value (US$ Mn), by Technology, 2018 to 2033
Table 55: Latin America Market Volume (Units), by Cancer Type, 2018 to 2033
Table 56: Latin America Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 57: Latin America Market Volume (Units), by End User, 2018 to 2033
Table 58: Latin America Market Value (US$ Mn), by End User, 2018 to 2033
Table 59: Latin America Market Volume (Units), by Country, 2018 to 2033
Table 60: Latin America Market Value (US$ Mn), by Country, 2018 to 2033
Table 61: Middle East and Africa Market Volume (Units), by Component, 2018 to 2033
Table 62: Middle East and Africa Market Value (US$ Mn), by Component, 2018 to 2033
Table 63: Middle East and Africa Market Volume (Units), by Technology, 2018 to 2033
Table 64: Middle East and Africa Market Value (US$ Mn), by Technology, 2018 to 2033
Table 65: Middle East and Africa Market Volume (Units), by Cancer Type, 2018 to 2033
Table 66: Middle East and Africa Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 67: Middle East and Africa Market Volume (Units), by End User, 2018 to 2033
Table 68: Middle East and Africa Market Value (US$ Mn), by End User, 2018 to 2033
Table 69: Middle East and Africa Market Volume (Units), by Country, 2018 to 2033
Table 70: Middle East and Africa Market Value (US$ Mn), by Country, 2018 to 2033
Table 71: Oceania Market Volume (Units), by Component, 2018 to 2033
Table 72: Oceania Market Value (US$ Mn), by Component, 2018 to 2033
Table 73: Oceania Market Volume (Units), by Technology, 2018 to 2033
Table 74: Oceania Market Value (US$ Mn), by Technology, 2018 to 2033
Table 75: Oceania Market Volume (Units), by Cancer Type, 2018 to 2033
Table 76: Oceania Market Value (US$ Mn), by Cancer Type, 2018 to 2033
Table 77: Oceania Market Volume (Units), by End User, 2018 to 2033
Table 78: Oceania Market Value (US$ Mn), by End User, 2018 to 2033
Table 79: Oceania Market Volume (Units), by Country, 2018 to 2033
Table 80: Oceania Market Value (US$ Mn), by Country, 2018 to 2033
List Of Figures
Figure 01: Global Market Volume (Units), Value (US$ Thousand) and Y-o-Y Growth, 2018 to 2033
Figure 02: Global Absolute $ Historical Market (2018-2022) and Absolute $ Opportunity (2023 to 2033), US$ Mn
Figure 03: Global Absolute Historical Volume Market (2018-2022) and Absolute Volume Opportunity (2023 to 2033), Units
Figure 04: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 05: Global Market Incremental $ Opportunity (US$ Thousand), 2023 to 2033
Figure 06: Global Market Share, By Component – 2023 to 2033
Figure 07: Global Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 08: Global Market Attractiveness Index, By Component – 2023 to 2033
Figure 09: Global Market Share, By Technology – 2023 to 2033
Figure 10: Global Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 11: Global Market Attractiveness Index, By Technology – 2023 to 2033
Figure 12: Global Market Share, By Cancer Type – 2023 to 2033
Figure 13: Global Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 14: Global Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 15: Global Market Share, By End User – 2023 to 2033
Figure 16: Global Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 17: Global Market Attractiveness Index, By End User – 2023 to 2033
Figure 18: Global Market Share, by Region – 2023 to 2033
Figure 19: Global Market Y-o-Y Growth Projections, by Region – 2023 to 2033
Figure 20: Global Market Attractiveness Index, by Region – 2023 to 2033
Figure 21: North America Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 22: Y-o-Y Growth Comparison of Market: North America Vs North America Countries Vs North America Average
Figure 23: North America Market Share, By Component – 2023 to 2033
Figure 24: North America Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 25: North America Market Attractiveness Index, By Component – 2023 to 2033
Figure 26: North America Market Share, By Technology – 2023 to 2033
Figure 27: North America Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 28: North America Market Attractiveness Index, By Technology – 2023 to 2033
Figure 29: North America Market Share, By Cancer Type – 2023 to 2033
Figure 30: North America Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 31: North America Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 32: North America Market Share, By End User – 2023 to 2033
Figure 33: North America Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 34: North America Market Attractiveness Index, By End User – 2023 to 2033
Figure 35: North America Market Share, By Country – 2023 to 2033
Figure 36: North America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 37: North America Market Attractiveness Index, By Country – 2023 to 2033
Figure 38: Europe Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 39: Y-o-Y Growth Comparison of Market: Europe Vs Europe Countries Vs Europe Average
Figure 40: Europe Market Share, By Component – 2023 to 2033
Figure 41: Europe Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 42: Europe Market Attractiveness Index, By Component – 2023 to 2033
Figure 43: Europe Market Share, By Technology – 2023 to 2033
Figure 44: Europe Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 45: Europe Market Attractiveness Index, By Technology – 2023 to 2033
Figure 46: Europe Market Share, By Cancer Type – 2023 to 2033
Figure 47: Europe Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 48: Europe Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 49: Europe Market Share, By End User – 2023 to 2033
Figure 50: Europe Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 51: Europe Market Attractiveness Index, By End User – 2023 to 2033
Figure 52: Europe Market Share, By Country – 2023 to 2033
Figure 53: Europe Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 54: Europe Market Attractiveness Index, By Country – 2023 to 2033
Figure 55: East Asia Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 56: Y-o-Y Growth Comparison of Market: East Asia Vs East Asia Countries Vs East Asia Average
Figure 57: East Asia Market Share, By Component – 2023 to 2033
Figure 58: East Asia Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 59: East Asia Market Attractiveness Index, By Component – 2023 to 2033
Figure 60: East Asia Market Share, By Technology – 2023 to 2033
Figure 61: East Asia Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 62: East Asia Market Attractiveness Index, By Technology – 2023 to 2033
Figure 63: East Asia Market Share, By Cancer Type – 2023 to 2033
Figure 64: East Asia Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 65: East Asia Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 66: East Asia Market Share, By End User – 2023 to 2033
Figure 67: East Asia Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 68: East Asia Market Attractiveness Index, By End User – 2023 to 2033
Figure 69: East Asia Market Share, By Country – 2023 to 2033
Figure 70: East Asia Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 71: East Asia Market Attractiveness Index, By Country – 2023 to 2033
Figure 72: South Asia Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 73: Y-o-Y Growth Comparison of Market: South Asia Vs South Asia Countries Vs South Asia Average
Figure 74: South Asia Market Share, By Component – 2023 to 2033
Figure 75: South Asia Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 76: South Asia Market Attractiveness Index, By Component – 2023 to 2033
Figure 77: South Asia Market Share, By Technology – 2023 to 2033
Figure 78: South Asia Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 79: South Asia Market Attractiveness Index, By Technology – 2023 to 2033
Figure 80: South Asia Market Share, By Cancer Type – 2023 to 2033
Figure 81: South Asia Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 82: South Asia Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 83: South Asia Market Share, By End User – 2023 to 2033
Figure 84: South Asia Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 85: South Asia Market Attractiveness Index, By End User – 2023 to 2033
Figure 86: South Asia Market Share, By Country – 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 88: South Asia Market Attractiveness Index, By Country – 2023 to 2033
Figure 89: Latin America Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 90: Y-o-Y Growth Comparison of Market: Latin America Vs Latin America Countries Vs Latin America Average
Figure 91: Latin America Market Share, By Component – 2023 to 2033
Figure 92: Latin America Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 93: Latin America Market Attractiveness Index, By Component – 2023 to 2033
Figure 94: Latin America Market Share, By Technology – 2023 to 2033
Figure 95: Latin America Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 96: Latin America Market Attractiveness Index, By Technology – 2023 to 2033
Figure 97: Latin America Market Share, By Cancer Type – 2023 to 2033
Figure 98: Latin America Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 99: Latin America Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 100: Latin America Market Share, By End User – 2023 to 2033
Figure 101: Latin America Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 102: Latin America Market Attractiveness Index, By End User – 2023 to 2033
Figure 103: Latin America Market Share, By Country – 2023 to 2033
Figure 104: Latin America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 105: Latin America Market Attractiveness Index, By Country – 2023 to 2033
Figure 106: MEA Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 107: Y-o-Y Growth Comparison of Market: MEA Vs MEA Countries Vs MEA Average
Figure 108: MEA Market Share, By Component – 2023 to 2033
Figure 109: MEA Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 110: MEA Market Attractiveness Index, By Component – 2023 to 2033
Figure 111: MEA Market Share, By Technology – 2023 to 2033
Figure 112: MEA Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 113: MEA Market Attractiveness Index, By Technology – 2023 to 2033
Figure 114: MEA Market Share, By Cancer Type – 2023 to 2033
Figure 115: MEA Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 116: MEA Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 117: MEA Market Share, By End User – 2023 to 2033
Figure 118: MEA Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 119: MEA Market Attractiveness Index, By End User – 2023 to 2033
Figure 120: MEA Market Share, By Country – 2023 to 2033
Figure 121: MEA Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 122: MEA Market Attractiveness Index, By Country – 2023 to 2033
Figure 123: Oceania Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2018 to 2033
Figure 124: Y-o-Y Growth Comparison of Market: Oceania Vs Oceania Countries Vs Oceania Average
Figure 125: Oceania Market Share, By Component – 2023 to 2033
Figure 126: Oceania Market Y-o-Y Growth Projections, By Component – 2023 to 2033
Figure 127: Oceania Market Attractiveness Index, By Component – 2023 to 2033
Figure 128: Oceania Market Share, By Technology – 2023 to 2033
Figure 129: Oceania Market Y-o-Y Growth Projections, By Technology – 2023 to 2033
Figure 130: Oceania Market Attractiveness Index, By Technology – 2023 to 2033
Figure 131: Oceania Market Share, By Cancer Type – 2023 to 2033
Figure 132: Oceania Market Y-o-Y Growth Projections, By Cancer Type – 2023 to 2033
Figure 133: Oceania Market Attractiveness Index, By Cancer Type – 2023 to 2033
Figure 134: Oceania Market Share, By End User – 2023 to 2033
Figure 135: Oceania Market Y-o-Y Growth Projections, By End User – 2023 to 2033
Figure 136: Oceania Market Attractiveness Index, By End User – 2023 to 2033
Figure 137: Oceania Market Share, By Country – 2023 to 2033
Figure 138: Oceania Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 139: Oceania Market Attractiveness Index, By Country – 2023 to 2033
Figure 140: United States Market share by Component, 2022
Figure 141: United States Market share by Technology, 2022
Figure 142: United States Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 143: United States Market Share by End User, 2022
Figure 144: Canada Market share by Component, 2022
Figure 145: Canada Market share by Technology, 2022
Figure 146: Canada Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 147: Canada Market Share by End User, 2022
Figure 148: Germany Market share by Component, 2022
Figure 149: Germany Market share by Technology, 2022
Figure 150: Germany Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 151: Germany Market Share by End User, 2022
Figure 152: United Kingdom Market share by Component, 2022
Figure 153: United Kingdom Market share by Technology, 2022
Figure 154: United Kingdom Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 155: United Kingdom Market Share by End User, 2022
Figure 156: France Market share by Component, 2022
Figure 157: France Market share by Technology, 2022
Figure 158: France Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 159: France Market Share by End User, 2022
Figure 160: Russia Market share by Component, 2022
Figure 161: Russia Market share by Technology, 2022
Figure 162: Russia Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 163: Russia Market Share by End User, 2022
Figure 164: Spain Market share by Component, 2022
Figure 165: Spain Market share by Technology, 2022
Figure 166: Spain Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 167: Spain Market Share by End User, 2022
Figure 168: Italy Market share by Component, 2022
Figure 169: Italy Market share by Technology, 2022
Figure 170: Italy Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 171: Italy Market Share by End User, 2022
Figure 172: China Market share by Component, 2022
Figure 173: China Market share by Technology, 2022
Figure 174: China Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 175: China Market Share by End User, 2022
Figure 176: Japan Market share by Component, 2022
Figure 177: Japan Market share by Technology, 2022
Figure 178: Japan Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 179: Japan Market Share by End User, 2022
Figure 180: South Korea Market share by Component, 2022
Figure 181: South Korea Market share by Technology, 2022
Figure 182: South Korea Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 183: South Korea Market Share by End User, 2022
Figure 184: India Market share by Component, 2022
Figure 185: India Market share by Technology, 2022
Figure 186: India Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 187: India Market Share by End User, 2022
Figure 188: Singapore Market share by Component, 2022
Figure 189: Singapore Market share by Technology, 2022
Figure 190: Singapore Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 191: Singapore Market Share by End User, 2022
Figure 192: Indonesia Market share by Component, 2022
Figure 193: Indonesia Market share by Technology, 2022
Figure 194: Indonesia Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 195: Indonesia Market Share by End User, 2022
Figure 196: Thailand Market share by Component, 2022
Figure 197: Thailand Market share by Technology, 2022
Figure 198: Thailand Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 199: Thailand Market Share by End User, 2022
Figure 200: Brazil Market share by Component, 2022
Figure 201: Brazil Market share by Technology, 2022
Figure 202: Brazil Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 203: Brazil Market Share by End User, 2022
Figure 204: Mexico Market share by Component, 2022
Figure 205: Mexico Market share by Technology, 2022
Figure 206: Mexico Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 207: Mexico Market Share by End User, 2022
Figure 208: Turkey Market share by Component, 2022
Figure 209: Turkey Market share by Technology, 2022
Figure 210: Turkey Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 211: Turkey Market Share by End User, 2022
Figure 212: GCC Countries Market share by Component, 2022
Figure 213: GCC Countries Market share by Technology, 2022
Figure 214: GCC Countries Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 215: GCC Countries Market Share by End User, 2022
Figure 216: South Africa Market share by Component, 2022
Figure 217: South Africa Market share by Technology, 2022
Figure 218: South Africa Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 219: South Africa Market Share by End User, 2022
Figure 220: Australia Market share by Component, 2022
Figure 221: Australia Market share by Technology, 2022
Figure 222: Australia Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 223: Australia Market Share by End User, 2022
Figure 224: New Zealand Market share by Component, 2022
Figure 225: New Zealand Market share by Technology, 2022
Figure 226: New Zealand Market Value (US$ Mn) and Forecast 2023 to 2033
Figure 227: New Zealand Market Share by End User, 2022
- FAQs -
Which product and service segment of the hemato oncology testing market is witnessing the highest growth?
Demand for assay kits & reagents is predicted to increase at a CAGR of 20% during the forecast period.
What is the value of the market for hemato oncology testing?
Worldwide hemato oncology testing demand is valued at US$ 4.33 billion in 2023.
How much will the hemato oncology testing market be valued by 2033?
Global sales of hemato oncology testing products are projected to reach US$ 23.64 billion by 2033.
What is the estimated CAGR for the hemato oncology testing market?
Demand for hemato oncology testing is predicted to increase rapidly at a CAGR of 18.5% from 2023 to 2033.
What are the major growth factors for the hemato oncology testing market?
Rising cases of hematologic cancer, advancements in diagnostic technologies, and growing collaborations & conferences on customized treatment procedures are driving market growth.
Hemato Oncology Testing Market